IRA rollover gift jump-starts finding a cure for Type 1 diabetes
When Peter Gottlieb, MD, started his residency, he already knew he wanted to do Type 1 diabetes research. His mother had developed the disease at age 52, and today his two children live with Type 1 diabetes. At CU Anschutz, Gottlieb has made significant strides during the last 23 years: in collaboration with Dr. Aaron Michels, he has started a biotech company, IMT to create and test a new therapy for Type 1 diabetes. This therapy would help someone with Type 1 diabetes maintain their insulin levels in the pancreas, allowing for a better quality of life and healthier body.
In order to support continued research that will hopefully discover a cure, Gottlieb and his wife, Gabriela, made a contribution from their individual retirement account to create an endowment, which will provide research support for years to come.
"I've been fortunate to work in an area I have a passion for and want to give something back for that," Gottlieb said. "We want to ensure the next generation of scientists have the same opportunity we have had."
Philanthropy is a key driver behind the research happening at the Barbara Davis Center for Diabetes, one of the largest diabetes institutes in the world, which is part of the CU School of Medicine and has a dedicated building on the CU Anschutz Medical Campus. Planned gifts like IRA contributions can create reliable sources of funding that researchers can confidently rely on year after year, and this allows researchers like Gottlieb to focus on finding a cure, not about next year's funding source.
Gottlieb is not only a philanthropist but also a beneficiary of philanthropy. One gift, provided by a grateful patient, enabled his team to start a project one and a half years earlier than planned. Because of this generosity, Gottlieb and his team applied for and received grants and developed the science to start IMT, which ultimately speeds up the process of finding a cure for Type 1 diabetes.